Nucleus RadioPharma
Redefining Radiopharmaceuticals
Redefining Radiopharmaceuticals
Nucleus RadioPharma is a health care startup founded in 2022 with a mission to redefine radiopharmaceuticals. The company's slogan "Redefining Radiopharmaceuticals" encapsulates its goal of transforming lives through leveraging world-class clinical, development, manufacturing, and supply chain expertise. Nucleus RadioPharma aims to bridge the gap between innovation and clinic, positioning itself as an industry leader in the field of radiopharmaceuticals.
The startup recently received a significant boost with a Series A investment on 05 June 2024, with AstraZeneca as the lead investor. This infusion of capital will undoubtedly enhance Nucleus RadioPharma's position in the market and accelerate its efforts to drive innovation and impact in the healthcare industry.
Nucleus RadioPharma's headquarters is located in the United States, strategically positioning the company within a hub of medical and technological innovation. As the startup continues to make strides in its field, it is poised to make substantial contributions to the advancement of radiopharmaceuticals and, ultimately, the improvement of patient care and outcomes.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | Unknown | 1 | AstraZeneca | 05 Jun 2024 |
| Series A | $56.00M | 8 |
|
17 Oct 2023 |
| Seed Round | $6.00M | 1 |
|
12 Oct 2022 |
No recent news or press coverage available for Nucleus RadioPharma.
We care about your data, and we'd love to use cookies make your experience better.
